News | July 23, 2007

Soft Drinks Linked To Heart Disease

July 24, 2007 - A new U.S. study published in the early online edition of Circulation, the journal of the American Heart Association, found that drinking more than one soft drink a day, whether regular or diet, may be linked to an increased risk of developing heart disease, due to an increase in metabolic syndrome.

The findings are part of the Framingham Heart Study (FHS), which was started in 1948 and now in its third generation of participants, grandchildren of the original cohort. The FHS looks at common factors or characteristics that contribute to cardiovascular disease (CVD) by following its development over a long period of time in a large group of people who joined before they had any overt symptoms of CVD or heart attack or stroke.

The FHS was started under the direction of the National Heart Institute (now known as the National Heart, Lung and Blood Institute or NHLBI).
"Moderation in anything is the key. If you are drinking one or more soft drinks a day, you may be increasing your risk of developing metabolic risk factors for heart disease," said Ravi Dhingra, M.D., an instructor in medicine at Harvard Medical School, and lead author of the study.

The study included 9,000 "person observations" taken at three different times over a four year period from participants enrolled in the FHS, all middle aged men and women. At the start of the four year observation period ("baseline"), the scientists established that participants who drank one or more soft drinks a day had a 48 percent higher chance of having metabolic syndrome than those who drank less.

Over the four year follow up, a longitudinal study of those participants who did not have metabolic syndrome at baseline (6,039 person observations) showed that drinking one or more soft drinks a day was linked to a 44 percent higher risk of getting metabolic syndrome for the first time.
Researchers found that participants who drank one or more soft drinks a day, when compared to those that drank less, had a number of increased risk factors for metabolic syndrome, including:

* 31 percent greater risk of developing new-onset obesity (defined as a body mass index or BMI of 30 kilograms per meter squared or higher).
* 30 percent higher risk of developing an increased waist circumference.
* 25 percent increased risk of developing high blood triglycerides or high fasting blood glucose.
* 32 percent increased risk of having low HDL ("good" cholesterol).
* A trend towards an increased risk of developing high blood pressure, but this was not statistically significant.

They also took data from a smaller separate group of participants who had filled in food questionnaires about their soft drink consumption and found that those participants who drank one or more diet or regular soda drinks a day had a 50 to 60 percent higher risk of developing new-onset metabolic syndrome.

The researchers adjusted the results to take into account a number of dietary and lifestyle factors of soft drink users. They adjusted for saturated fat and trans fat intake, dietary fibre, total caloric intake, smoking and physical activity, but, as Vasan said, they "still observed a significant association of soft drink consumption and risk of developing the metabolic syndrome and multiple metabolic risk factors".
Vasan speculates that perhaps the fructose corn syrup in regular soft drinks causes weight gain, or leads to insulin resistance and diabetes, but if that were the case you would expect to see the link with regular drinks and not with diet drinks.

One theory is that the caramel in soft drinks could stimulate the development of complex sugars (high glycation end products) that result in insulin resistance and cause inflammation, as shown by some experimental studies.

The researchers said it was important to realize that these are just theories, and their study had only found a link between soft drinks and metabolic syndrome, it had not established that one causes the other.

"Soft Drink Consumption and Risk of Developing Cardiometabolic Risk Factors and the Metabolic Syndrome in Middle-Aged Adults in the Community." Ravi Dhingra, Lisa Sullivan, Paul F. Jacques, Thomas J. Wang, Caroline S. Fox, James B. Meigs, Ralph B. D'Agostino, J. Michael Gaziano and Ramachandran S. Vasan.

For more information: http://www.americanheart.org/presenter.jhtml?identifier=4756

For the abstract: http://circ.ahajournals.org/cgi/content/abstract/CIRCULATIONAHA.107.689935v1


Related Content

News | Cardiovascular Clinical Studies

April 24, 2024 β€”Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 β€” Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 β€” CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 β€” Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 β€” People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 β€” Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

Home April 09, 2024
Home
Subscribe Now